Kim Y S, Nibbelink D W, Overall J E
Du Pont Merck Pharmaceutical Company, Wilmington, DE 19880-0027.
J Clin Psychol. 1993 Jan;49(1):61-71. doi: 10.1002/1097-4679(199301)49:1<61::aid-jclp2270490109>3.0.co;2-b.
The SKT (Syndrom Kurztest) has been used in the assessment of treatment responses in numerous clinical trials for treatment of dementia in German-speaking Europe. Data from 265 patients with mild to moderate Alzheimer's disease in a study conducted in the U.S. were analyzed to evaluate factor structure, common and specific subtest content, reliability, and concurrent validity. Results confirm the presence of two primary factors of memory and attention. Test-retest reliability of the factor scores was estimated to be .75 and .93. Test-retest reliability of the composite SKT total score was .90. The correlations between the SKT memory and attention factor scores and the MMSE and ADAS measurements of dementia also support validity with regard to the broader construct of cognitive dysfunction.
SKT（综合征简短测试）已在德语区欧洲用于评估众多痴呆症治疗临床试验中的治疗反应。对美国一项研究中265名轻度至中度阿尔茨海默病患者的数据进行分析，以评估因子结构、共同和特定子测试内容、信度和同时效度。结果证实存在记忆和注意力两个主要因子。因子得分的重测信度估计为0.75和0.93。SKT综合总分的重测信度为0.90。SKT记忆和注意力因子得分与痴呆症的MMSE和ADAS测量值之间的相关性也支持其在更广泛认知功能障碍结构方面的效度。
